Juan D Arias1, Andrea T Hoyos2, Betzy Alcántara3, Ronald M Sanchez-Avila4, Francisco J Arango2, Virgilio Galvis5. 1. FOSCAL Internacional, Centro Oftalmológico Virgilio Galvis, Universidad Autónoma de Bucaramanga, Floridablanca, Colombia. 2. FOSCAL Internacional, Universidad Autónoma de Bucaramanga, Floridablanca, Colombia. 3. Hospital Central de las Fuerzas Armadas, Santo Domingo, Dominican Republic. 4. Fundación de Investigación Oftalmológica, Instituto Universitario Fernández-Vega, Oviedo, Spain; and. 5. FOSCAL Internacional, Universidad Autónoma de Centro Oftalmológico Virgilio Galvis Floridablanca, Colombia.
Abstract
PURPOSE: Persistent macular hole (PMH) is a challenge for retina surgeons. There are limited surgical techniques described achieving PMH closure. For more than a decade, techniques with blood derivatives have been described without optimal outcomes. The aim of this article is to report the usefulness of the plasma rich in growth factors (PRGF) as a new way to improve PMH closure. METHODS: This is an observational study. Two patients with PMH were chosen at the FOSCAL Internacional, Floridablanca, Colombia. For each patient, a complete ophthalmological examination before and after treatment was performed. It included best-corrected visual acuity and fundus examination. Features of swept-source optical coherence tomographic angiography (Topcon) at baseline and after treatment were included. Preoperative evaluation included the following: previous vitreoretinal surgery for macular hole, macular hole measurement and classification, and dissociated optic nerve fiber layer in en-face map, confirming a prior internal limiting membrane peeling. Plasma rich in growth factors-Endoret technology is characterized by moderate platelet concentration and absence of leukocytes, which requires calcium chloride for platelet activation. It is obtained from each patient's blood sample, submitted to a series of processes to acquire a three-dimensional fibrin scaffold, rich in hundreds of proteins, which seems to have therapeutic potential. This PRGF membrane is placed into the macular hole with forceps through a pars plana vitrectomy after complete air-fluid exchange. Supernatant was placed on the macula and left it for 2 minutes. It is then aspirated, and gas or silicone oil was left as a tamponade. RESULTS: Follow-up period was of 12 months for each patient. Complete macular hole closure was achieved in both cases. Best-corrected visual acuity changed from 20/200 preoperatively to 20/100 postoperatively in Patient #1 and from 20/1,500 to 20/100 in Patient #2. CONCLUSION: Plasma rich in growth factors has been primarily investigated for ocular surface diseases. This is a pilot study using this technology for PMH treatment. The use of PRGF may be an effective and safe surgical technique with satisfactory anatomical and functional results for PMH. Because of its own biomaterials and proteins, PRGF not only allows anatomical closure but also seems to stimulate tissue regeneration.
PURPOSE: Persistent macular hole (PMH) is a challenge for retina surgeons. There are limited surgical techniques described achieving PMH closure. For more than a decade, techniques with blood derivatives have been described without optimal outcomes. The aim of this article is to report the usefulness of the plasma rich in growth factors (PRGF) as a new way to improve PMH closure. METHODS: This is an observational study. Two patients with PMH were chosen at the FOSCAL Internacional, Floridablanca, Colombia. For each patient, a complete ophthalmological examination before and after treatment was performed. It included best-corrected visual acuity and fundus examination. Features of swept-source optical coherence tomographic angiography (Topcon) at baseline and after treatment were included. Preoperative evaluation included the following: previous vitreoretinal surgery for macular hole, macular hole measurement and classification, and dissociated optic nerve fiber layer in en-face map, confirming a prior internal limiting membrane peeling. Plasma rich in growth factors-Endoret technology is characterized by moderate platelet concentration and absence of leukocytes, which requires calcium chloride for platelet activation. It is obtained from each patient's blood sample, submitted to a series of processes to acquire a three-dimensional fibrin scaffold, rich in hundreds of proteins, which seems to have therapeutic potential. This PRGF membrane is placed into the macular hole with forceps through a pars plana vitrectomy after complete air-fluid exchange. Supernatant was placed on the macula and left it for 2 minutes. It is then aspirated, and gas or silicone oil was left as a tamponade. RESULTS: Follow-up period was of 12 months for each patient. Complete macular hole closure was achieved in both cases. Best-corrected visual acuity changed from 20/200 preoperatively to 20/100 postoperatively in Patient #1 and from 20/1,500 to 20/100 in Patient #2. CONCLUSION: Plasma rich in growth factors has been primarily investigated for ocular surface diseases. This is a pilot study using this technology for PMH treatment. The use of PRGF may be an effective and safe surgical technique with satisfactory anatomical and functional results for PMH. Because of its own biomaterials and proteins, PRGF not only allows anatomical closure but also seems to stimulate tissue regeneration.
Authors: Ronald M Sánchez-Ávila; Carlos A Robayo-Esper; Eva Villota-Deleu; Álvaro Fernández-Vega Sanz; Álvaro Fernández-Vega González; Borja de la Sen-Corcuera; Eduardo Anitua; Jesús Merayo-Lloves Journal: Clin Pract Date: 2022-01-10
Authors: Carlota Suárez-Barrio; Susana Del Olmo-Aguado; Eva García-Pérez; Enol Artime; María de la Fuente; Francisco Muruzabal; Eduardo Anitua; Begoña Baamonde-Arbaiza; Luis Fernández-Vega; Jesús Merayo-Lloves Journal: Int J Mol Sci Date: 2020-10-09 Impact factor: 5.923